Acadia Pharmaceuticals Inc (ACAD) Stock Price & Analysis
Acadia Pharmaceuticals Inc (ACAD) rose 0.04% to USD 24.84 as of July 25, 2026 at 03:02 UTC, according to Nexqual real-time market data.
ACAD last closed at USD 24.83; the session ranged USD 24.57–25.1 on volume of 982,562 shares. Market capitalization is $4.25B, with a 52-week range of USD 19.69–28.35 (NMS). Source: Nexqual, July 25, 2026 at 03:02 UTC.
Key Statistics (as of July 25, 2026 at 03:02 UTC)
| Price | USD 24.84 |
|---|---|
| Change | ▲ 0.04% (up) |
| Previous Close | USD 24.83 |
| Open | USD 25.1 |
| Day Range | USD 24.57 – 25.1 |
| 52-Week Range | USD 19.69 – 28.35 |
| Volume | 982,562 shares |
| Market Cap | $4.25B |
| Exchange | NMS |
Technical Analysis (ACAD)
Nexqual's technical model rates ACAD "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 03:02 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 53.27 (neutral) |
| vs SMA50 | Above (USD 23.17) |
| MACD | 0.51 (positive) |
Analyst Ratings (ACAD)
Wall Street analysts rate ACAD "Buy" based on 20 analysts, with a mean price target of USD 32.8 (range USD 17–45), per Nexqual as of July 25, 2026 at 03:02 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 20 |
| Mean Target | USD 32.8 |
| High Target | USD 45 |
| Low Target | USD 17 |
| Buy / Hold / Sell | 16 / 4 / 1 |
Earnings (ACAD)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD 0.04 |
| Revenue Estimate | $295.52M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.02 vs est 0.08 ▼ miss |
| 2025-12-31 | USD 0.14 vs est 0.14 ▼ miss |
| 2025-09-30 | USD 0.42 vs est 0.15 ▲ beat |
| 2025-06-30 | USD 0.16 vs est 0.14 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:02 UTC.
Financials & Fundamentals (ACAD)
| Total Revenue | $1.10B |
|---|---|
| Revenue Growth (YoY) | +9.70% |
| Gross Margin | +61.58% |
| Operating Margin | -1.72% |
| Profit Margin | +34.30% |
| ROE | +37.32% |
| Debt / Equity | 4.07 |
| Current Ratio | 3.59 |
| Total Cash | $851.46M |
| Total Debt | $50.79M |
| Free Cash Flow | $154.14M |
Source: Nexqual, July 25, 2026 at 03:02 UTC.
Financial Health Score (ACAD)
Nexqual rates Acadia Pharmaceuticals Inc's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 03:02 UTC.
| Growth | Solid — Revenue +12% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 62%, operating -2% |
| Balance Sheet | Strong — $851M cash vs $51M debt, net cash position |
| Cash Flow | Solid — FCF $154M, 14% margin |
| Efficiency | Strong — ROE 37%, ROA 3.7% |
Ownership (ACAD)
| Insider Ownership | +0.32% |
|---|---|
| Institutional Ownership | +98.93% |
| Shares Outstanding | 171.24M |
| Float | 127.19M |
| Short % of Float | +10.14% |
Source: Nexqual, July 25, 2026 at 03:02 UTC.
Leadership (ACAD)
Acadia Pharmaceuticals Inc is led by Catherine E. Owen Adams (age 55), CEO & Director, per Nexqual as of July 25, 2026 at 03:02 UTC.
| CEO & Director | Catherine E. Owen Adams (age 55) |
|---|---|
| Executive VP & CFO | Mark C. Schneyer (age 51) |
| Senior Vice President of Investor Relations & Corporate Communications | Albert S. Kildani |
| Senior Vice President of Finance | James K. Kihara (age 44) |
| Senior Vice President of Rare Disease Franchise | Allyson McMillan-Youngblood |
Major Backers & Investors (ACAD)
Notable institutional backers of Acadia Pharmaceuticals Inc include Baker Bros. Advisors, LP, RTW Investments LP, First Trust Advisors LP, according to Nexqual as of July 25, 2026 at 03:02 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baker Bros. Advisors, LP | 25.05% |
| RTW Investments LP | 4.17% |
| First Trust Advisors LP | 1.95% |
| Palo Alto Investors Lp | 1.68% |
| Fidelity | 0.73% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 19.49% |
| Vanguard Group | 14.23% |
| State Street | 7.86% |
| Geode Capital | 2.02% |
| Dimensional Fund Advisors | 1.84% |
Source: Nexqual, July 25, 2026 at 03:02 UTC.
From Acadia Pharmaceuticals Inc's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
- The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
- It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial.
- In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SRPT | Sarepta Therapeutics, Inc. | USD 15.68 | ▼ 0.88% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 271.77 | ▲ 1.79% |
| BMRN | BioMarin Pharmaceutical Inc. | USD 59.33 | ▲ 1.59% |
| CLDX | Celldex Therapeutics, Inc. | USD 35.28 | ▲ 1.47% |
| EXEL | Exelixis, Inc. | USD 55.37 | ▲ 0.71% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:02 UTC. This page is informational and not investment advice.